AR059220A1 - Composiciones sinergisticas para el tratamiento del vih - Google Patents

Composiciones sinergisticas para el tratamiento del vih

Info

Publication number
AR059220A1
AR059220A1 ARP070100361A ARP070100361A AR059220A1 AR 059220 A1 AR059220 A1 AR 059220A1 AR P070100361 A ARP070100361 A AR P070100361A AR P070100361 A ARP070100361 A AR P070100361A AR 059220 A1 AR059220 A1 AR 059220A1
Authority
AR
Argentina
Prior art keywords
ccr5
hiv
virus
treatment
prevention
Prior art date
Application number
ARP070100361A
Other languages
English (en)
Inventor
Chanhua Ji
Suryanarayana Sankuratri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR059220A1 publication Critical patent/AR059220A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones farmacéuticas sinergísticas para el tratamiento o prevencion de infecciones por VIH-1 que comprenden anticuerpos monoclonales anti-CCR5 y antagonistas del CCR5, inhibidores de la fusion del virus o inhibidores de la union del virus. Las composiciones muestran una actividad significativamente mayor de la que se anticipa de la actividad de cada uno de los componentes individuales. También se proporcionan métodos para el tratamiento o prevencion del VIH-1 utilizando las mismas. Reivindicacion 1: Una composicion farmacéutica que comprende una cantidad terapéuticamente efectiva de una combinacion sinergística que comprende un anticuerpo aislado, que se une al receptor CCR5 y en el que la secuencia de la CDR3 de la cadena pesada variable de dicho anticuerpo es la del ID. de SEC. N° 9 o 10, y un antagonista de CCR5, un inhibidor de la fusion del virus o un inhibidor de la union del virus.
ARP070100361A 2006-01-30 2007-01-29 Composiciones sinergisticas para el tratamiento del vih AR059220A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77209406P 2006-01-30 2006-01-30

Publications (1)

Publication Number Publication Date
AR059220A1 true AR059220A1 (es) 2008-03-19

Family

ID=38226611

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100361A AR059220A1 (es) 2006-01-30 2007-01-29 Composiciones sinergisticas para el tratamiento del vih

Country Status (8)

Country Link
US (1) US20080299132A1 (es)
EP (1) EP1981911A2 (es)
JP (1) JP2009525301A (es)
CN (1) CN101410414A (es)
AR (1) AR059220A1 (es)
CA (1) CA2637463A1 (es)
TW (1) TW200738264A (es)
WO (1) WO2007085567A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090127298A (ko) * 2007-03-29 2009-12-10 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
WO2009037168A1 (en) * 2007-09-19 2009-03-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
JP2011519888A (ja) * 2008-05-09 2011-07-14 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環式化合物
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2088158A3 (en) * 1998-12-16 2010-01-20 Progenics Pharmaceuticals, Inc. Monoclonal antibody against the CCR5 chemokine receptor
TW200720289A (en) * 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof

Also Published As

Publication number Publication date
WO2007085567A2 (en) 2007-08-02
CN101410414A (zh) 2009-04-15
JP2009525301A (ja) 2009-07-09
WO2007085567A3 (en) 2007-10-11
EP1981911A2 (en) 2008-10-22
TW200738264A (en) 2007-10-16
CA2637463A1 (en) 2007-08-02
US20080299132A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
CL2022000328A1 (es) Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017)
CL2021002657A1 (es) Un anticuerpo antagonista que se une específicamente a vista humano, una composición farmacéutica que lo comprende; y eso uso de los mismos para el tratamiento del cáncer o una enfermedad infecciosa (divisional de la solicitud 201802925)
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
CL2017002686A1 (es) Métodos para tratar o prevenir dolor de cabeza por migraña
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
NO20065252L (no) Behandling av forstyrrelser
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
PE20090227A1 (es) Composiciones farmaceuticas que comprenden agentes anti-beta-klotho
UY27992A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht
PE20160671A1 (es) Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
PE20090239A1 (es) ANTAGONISTAS CRIg
PE20081264A1 (es) Anticuerpos agonistas anti-notch3
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
ECSP10010439A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
PE20141693A1 (es) Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
PE20091655A1 (es) Farmaco para el cancer de higado
NZ569428A (en) Treatment of conditions involving demyelination with a Sp35 antagonist
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Legal Events

Date Code Title Description
FB Suspension of granting procedure